Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.

U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab

The Centers for Disease Control and Prevention (CDC) recommended mRNA-based COVID-19 vaccines from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) or Moderna Inc (NASDAQ: MRNA) over Johnson & Johnson's (NYSE: JNJ), which has been linked to rare but serious blood clots. The CDC recommended following a 15 to 0 vote by advisers encouraging the use of vaccines other than J&J's.

CDC Backs mRNA COVID-19 Vaccines Over Johnson & Johnson's, Citing Higher Rates Of Clotting Cases: Report

COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no antibodies against omicron in a study, reports Bloomberg. Researchers at the University of Washington and Humabs Biomed SA analyzed the efficacy of six vaccines.

Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study

The stock price of Johnson & Johnson has outperformed the broader indices over the last month or so. While the S&P500 index has seen a rise of 1% over the last one month, JNJ stock is up around 5%.

Johnson & Johnson Stock Is Likely To See Higher Levels In The Near Term

The shares of Johnson & Johnson (NYSE: JNJ) have received a $161 price target from Goldman Sachs. These are the details.

Johnson & Johnson Stock (JNJ): $161 Price Target From Goldman Sachs

Moderna

Pfizer

The CDC has not yet decided if it will accept the recommendation and remove the shot from the market.

Moderna, Pfizer Covid Vaccines Should Be Given Over Johnson & Johnson's, CDC Advisory Board Says

The Centers for Disease Control and Prevention recommended Pfizer and Moderna Covid vaccines over the Johnson & Johnson vaccine.

CDC expert panel prefers Pfizer, Moderna vaccines over J&J shots for adults due to rare blood clot cases

AbbVie

Both of these two healthcare stocks have potential. Which one has a better year ahead?

Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson?

The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.

J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is set to meet Thursday to discuss safety concerns associated with Johnson & Johnson's JNJ, +0.50% COVID-19 vaccine. The shot has raised concern due to the risk of thrombocytopenia syndrome, a type of rare blood clot that occurs with low platelets.

CDC committee to meet Thursday, to discuss blood-clot risk associated with J&J's COVID-19 vaccine

Preferred Apartment Communities

Kinder Morgan

PepsiCo

Provident Financial Services

Procter & Gamble

STORE Capital

Viatris

Vanguard High Dividend Yield ETF

Exxon Mobil

I invested quite a bit into the VYM ETF. This has helped me amass an investment with Vanguard of over $40,000+ since last year!

Dividend Stock Purchase: Lanny's November 2021 Summary

Coca-Cola

Walmart

Capital is rotating into consumer staples stocks as investors play defense. These three leaders in the sector are good stocks to buy.

3 Consumer Staples Stocks to Buy for Safety

EMA's human medicines committee (CHMP) has concluded that a booster dose of Johnson & Johnson's (NYSE: PFE) COVID-19 vaccine may be considered at least two months after the first dose in people aged 18 years and above. The recommendation follows data showing that a booster dose of COVID-19 vaccine given at least two months after the first dose in adults led to a rise in antibodies against SARS-CoV-2.

European Medicines Committee Backs Johnson & Johnson's COVID-19 Booster Dose

CHMP recommendation based on data showing a booster (second shot) of the Johnson & Johnson COVID-19 vaccine increased protection to 75 percent against symptomatic COVID-19 infection globally Data also demonstrated 100 percent protection against severe COVID-19, at least 14 days post-booster vaccination The Johnson & Johnson COVID-19 vaccine, when given as a booster or primary shot, was generally well-tolerated NEW BRUNSWICK, N.J., Dec. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a 'mix and match' booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting).

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

The European Medicines Agency said it will recommend Johnson & Johnson's JNJ, +1.09% COVID-19 vaccine as a booster dose when administered at least two month after the first in those 18 years and older. That follows data showing that a booster given in that time frame led to a rise in in antibodies against SARS-CoV-2, the virus that causes COVID-19, the agency said in a press release on Wednesday.

European Medicines Agency to recommend Johnson & Johnson COVID booster

Sanofi

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at the American Society of Hematology (ASH) 2021 Annual Meeting.

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients

The U.S. Supreme Court on Monday declined to hear a bid by Johnson & Johnson to throw out a lawsuit brought by the state of Mississippi over allegations that the company failed to inform residents that its talc-based products increased the risks of developing ovarian cancer.

U.S. Supreme Court snubs J&J's bid to avoid Mississippi talc lawsuit

Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary has received Conditional Marketing Authorization (CMA) approval from the European Commission for Rybrevant (amivantamab) for advanced non-small cell lung cancer (NSCLC). The approval comes for activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations after the failure of platinum-based therapy.

Janssen Secures Conditional EU Marketing Authorization For Rybrevant in Lung Cancer Setting

Apple

Celsius Holdings

Civitas Resources

Cisco Systems

Chevron

Dow Inc

Enphase Energy

Intel

Intrepid Potash

McDonald's

Microsoft

Trillium Therapeutics

Two sample Breakout Stocks for Week 50 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week 1 stock beat 10% peak gains in HIMX +13.2% despite high negative Momentum Gauge® values from November continuing through the week.

Week 50 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

AstraZeneca

BioNTech SE

It depends on what data the FDA requires.

How Quickly Could Vaccines Targeting the Omicron Variant Be Available?

Novavax

It looks like the winners will keep winning.

What Does the Omicron Variant Mean for Vaccine Stocks?

General Electric

With Johnson & Johnson, Toshiba, and GE Splitting, Could Other Big Companies Follow Suit?

ABM Industries

Aflac

Arrow Financial

Franklin Resources

Dividend Champions can form the cornerstone of any income-oriented portfolio, but most of us don't have enough time to analyze all 139 stocks thoroughly. To represent the trade-off between quality and price, we group the candidates into three categories, namely “Attractive Value”, “Expensive But Worth It” and “Best of Best”.

News for Johnson & Johnson Stock (JNJ)